

1 Host and microbiome features of secondary infections in lethal covid-19

2 Martin Zacharias^{1#}, Karl Kashofer^{1#}, Philipp Wurm^{1#}, Peter Regitnig¹, Moritz Schütte², Margit
3 Neger¹, Sandra Ehmann¹, Leigh M. Marsh³, Grazyna Kwapiszewska³, Martina Loibner¹, Anna
4 Birnhuber³, Eva Leitner⁴, Andrea Thüringer¹, Elke Winter¹, Stefan Sauer¹, Marion J.
5 Pollheimer¹, Fotini R. Vagena¹, Carolin Lackner¹, Barbara Jelusic¹, Lesley Ogilvie², Marija
6 Durdevic¹, Bernd Timmermann⁵, Hans Lehrach^{2,5}, Kurt Zatloukal^{1*}, and Gregor Gorkiewicz^{1*}

7
8
9 ¹ Diagnostic and Research Institute of Pathology, Medical University of Graz, Neue
10 Stiftingtalstrasse 6, A-8010 Graz, Austria

11 ² Alacris Theranostics GmbH, Max-Planck-Strasse 3, D-12489 Berlin, Germany

12 ³ Ludwig Boltzmann Institute for Lung Vascular Research, Neue Stiftingtalstrasse 6/VI, A-8010
13 Graz, Austria

14 ⁴ Diagnostic and Research Institute of Hygiene, Microbiology and Environmental Medicine,
15 Medical University of Graz, Neue Stiftingtalstrasse 6, A-8010 Graz, Austria

16 ⁵ Max Planck Institute for Molecular Genetics, Ihnestrasse 63, D-14195 Berlin, Germany

17

18 #contributed equally

19 *correspondence:

20 Gregor Gorkiewicz, MD

21 Diagnostic and Research Institute for Pathology, Medical University of Graz

22 Neue Stiftingtalstrasse 6, A-8010 Graz, Austria

23 Phone: +43-316-385-71743

24 Email: gregor.gorkiewicz@medunigraz.at

25 ORCID: 0000-0003-1149-4782

26 Kurt Zatloukal, MD

27 Diagnostic and Research Institute for Pathology, Medical University of Graz

28 Neue Stiftingtalstrasse 6, A-8010 Graz, Austria

29 Phone: +43-316-385-71732

30 Email: kurt.zatloukal@medunigraz.at

31 ORCID: 0000-0001-5299-7218

32

33

34

35 **Keywords:** Covid-19, autopsy, metatranscriptome, lung microbiome, diffuse alveolar damage,

36 secondary infections, macrophages, complement C1q, immune exhaustion, immune-

37 **NOTE:** This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

checkpoints

38 **Abstract**

39 Secondary infections contribute significantly to covid-19 mortality but host and microbial
40 factors driving this sequel remain poorly understood. We performed an autopsy study of 20
41 covid-19 cases and 14 controls from the first pandemic wave. Autopsies combined with
42 microbial cultivation and deep RNA sequencing (RNAseq) allowed us to define major organ
43 pathologies and specify secondary infections. Lethal covid-19 segregated into two main death
44 causes separating cases with either dominant diffuse alveolar damage (DAD) or secondary
45 infections of lungs. Lung microbiome changes were profound in covid-19 showing a reduced
46 biodiversity and increased presence of prototypical bacterial and fungal pathogens in cases
47 with secondary infections. Deep RNAseq of lung tissues distinctly mirrored death causes and
48 cellular deconvolution stratified DAD cases into subgroups with different cellular
49 compositions. Myeloid cells, including macrophages, and complement C1q activation were
50 found to be strong stratifying factors suggesting a pathophysiological link possibly leading to
51 tolerance in DAD subgroups. Moreover, several signs of immune-impairment were evident in
52 covid-19 lungs including strong induction of inhibitory immune-checkpoints. Thus, our study
53 highlights profound alterations of the local immunity in covid-19, wherein immune-
54 impairment leads to reduced antimicrobial defense favoring the development of secondary
55 infections on top of SARS-CoV-2 infection.

56

57

58

59

60

61

62 **Introduction**

63 Covid-19 originates from infection of the upper respiratory tract with SARS-CoV-2,
64 which can progress into severe acute lung injury (ALI). Based on the tissue-typic expression of
65 the viral host-entry receptor ACE2 and certain proteases (e.g. TMPRSS2) facilitating cellular
66 uptake, also other organs like the kidney could be directly infected [1]. In addition, severe
67 disturbance of immune and coagulation systems during covid-19 lead to a multifaceted
68 disease with variable multi-organ damages [2]. A consistent finding in severe covid-19 is initial
69 immune hyperactivation (called "cytokine storm") leading to subsequent immune exhaustion,
70 a phenomenon also known in other severe infections [3-6]. Consequently, secondary
71 infections which develop on top of SARS-CoV-2 infection contribute significantly to covid-19
72 mortality similar to severe influenza [7]. Curiously, the pathophysiology leading to the
73 development of secondary lung infections is generally poorly understood. We performed an
74 autopsy study of 20 consecutive covid-19 patients, who died during the first pandemic wave.
75 Full autopsies were performed and various specimen types were collected for tissue-based
76 investigations, molecular measures including deep sequencing and cultivation of virus and
77 other microbes. Integrating all the information gained from this "holistic" autopsy approach
78 allowed us to gain a deeper understanding of host and microbial factors contributing to
79 secondary infections as a major sequel of lethal covid-19.

80


81 **Autopsy cohort, SARS-CoV-2 body distribution and genotyping**

82 Twenty consecutive covid-19 patients were examined post-mortem (Figure S1).
83 Thirteen cases were males and 7 were females, their age ranged from 53 to 93 years (median:
84 79 years). All had multiple comorbidities typically prevalent in severe covid-19. In addition, 14
85 age-matched non-covid-19 controls who died within the same time period were included for

86 comparisons (Tables S1 and S2). Patients were tested for SARS-CoV-2 tissue distributions by
87 quantitative RT-PCR (target: nucleocapsid-gene) and most positive samples with the highest
88 viral loads originated from the respiratory tract, followed by myocardium, liver, kidney and
89 pleural effusions. Other tissues and body liquids were positive only in single cases or tested
90 overall negative (Figure 1A). Notably, deep RNAseq generated from lung tissues revealed
91 SARS-CoV-2 transcripts in each covid-19 case, including the four qRT-PCR negative ones,
92 showing increased sensitivity of deep transcriptomic analysis (127±29 million reads were
93 generated per sample on average; Figure 1B). The viral genome was entirely captured by deep
94 RNAseq from lung tissues yielding more plus-strand reads (mean: 37.89 reads per million;
95 range: 0.02-131,165.41) than minus-strand reads (mean: 1.81 reads per million; range: 0-
96 484.81; Figure 1C). In addition, 11 SARS-CoV-2 strains could be cultivated from post-mortem
97 lung tissues using Vero cells (Table S3). Successful virus cultivation significantly correlated with
98 abundance of SARS-CoV-2 reads (Figure 1D and S2).

99 SARS-CoV-2 genotyping facilitated by PCR and sequencing directly from autopsy
100 specimens yielded 14 complete viral genomes (Table S4). Nine different sequence variants
101 were detected showing up to 12 nucleotide changes compared to the reference (SARS-CoV-2
102 Wuhan-Hu-1; total genome size 29,903 bp; Table S5). Strains corresponded to the pangolin
103 lineages B.1.22, B1.5, B and B.1.160.1, respectively (clades 19A and 20A), representing the
104 dominant genotypes of the first pandemic wave (Figure 1E). Twelve strains harbored a D614G
105 mutation in the spike (S) protein, which leads to increased viral transmissibility and, therefore,
106 this genotype superseded the wild-type strain already early in the pandemic [8]. We identified
107 also 2 viral clusters in our cohort, cluster 1 (case 3, 4, 6, 8, and 9) and cluster 2 (case 1, 2, and
108 5), respectively (Figure 1F).

109



110

111 **Figure 1. SARS-CoV-2 tissue distributions, genotyping and virus cultivation.** (A) SARS-CoV-2
 112 loads (compared to human glyceraldehyde 3-phosphate dehydrogenase, GAPDH) and tissue
 113 distributions derived from post mortem sampling (median highlighted). Case numbers are
 114 given on the right. (B) Significant association of qRT-PCR positivity (n-gene) with viral loads
 115 determined by RNAseq of lung tissues (Mann-Whitney test). (C) Distribution of viral reads
 116 generated from lung tissues along the SARS-CoV-2 genome. Cumulative coverage of plus and
 117 minus strand transcripts is shown (median in bold). Identified nucleotide and amino-acid
 118 changes in comparison to the Wuhan reference strain are indicated. (D) Correlation of SARS-
 119 CoV-2 plus and minus strand reads with cultivation (Spearman correlation). Triangles specify
 120 cultivation-positive samples. EM picture showing viral particles in Vero CCL-81 cells (arrows).
 121 (E) Cladogram showing detected virus genotypes within a global context. The Wuhan


122 reference strain (center) and the UK variant B.1.1.7 (Ecuador/INSPI-179112/2021) are
123 included for comparisons. The pangolin lineage designation is used to specify viral genotypes.
124 (F) Dendrogram showing detected viral genotypes. Corresponding mutations in the S protein
125 are indicated and virus strains are color coded accordingly.
126

127 Notably, cases 6, 8 and 9 from cluster 1 originated from the same residential care home and
128 all cases from cluster 2 stayed in the same hospital ward prior to covid-19. Thus, it is very likely
129 that these individuals were infected from the same sources and/or transmission occurred.

130

131 **Major organ pathologies and death causes**

132 Lungs showed the dominant pathologies in relation to covid-19, only one case (#1)
133 presented with acute myocardial infarction as the ascribed death cause. Diffuse alveolar
134 damage (DAD), the histopathological representation of ALI, in a patchy distribution and often
135 prevalent in multiple lung segments was the major finding in 11 cases. Early exudative stages
136 and later organizing stages of DAD were found within the same patient together, often
137 adjacent to nearly normal or less affected parenchyma indicating ongoing tissue damage
138 (Figures 2A and S3-S5). Also, a significant positive correlation of SARS-CoV-2 loads from
139 nasopharyngeal tissues compared to lungs was found (Figure 2B), which suggests active
140 seeding of infectious particles from the upper respiratory tract likely via micro-aspiration into
141 the lungs [1]. Microscopic features of lungs were extensively assessed (see methods for details
142 of scoring histopathological changes) to specify and grade the severity of lesions and also to
143 capture the heterogeneity of different lung pathologies. Features greatly varied between
144 cases and no pattern clearly correlated with disease duration (defined as the interval between
145 the first SARS-CoV-2 positive PCR and death) or viral loads (Figure 2C). Importantly, the
146 clearest discriminating feature of cases was the presence of neutrophilic granulocytes,
147 indicative of secondary infections (i.e. "pneumonia"), in comparison to DAD.



148
149

150 **Figure 2. Lung pathology of lethal covid-19 stratifies into diffuse alveolar damage and**
 151 **pneumonia.** (A) Histological representation of diffuse alveolar damage (DAD) in lungs. A
 152 patchy representation of DAD is shown (left). Hyaline membranes (arrows) as a hallmark
 153 lesion of early DAD (top right). Immunohistochemical detection (nucleoprotein antibody) of
 154 SARS-CoV-2 infected pneumocytes (bottom right). (B) (Top) Immunohistochemical detection
 155 of SARS-CoV-2 infected respiratory epithelium of the nasopharynx. (Bottom) Correlation
 156 between SARS-CoV-2 loads in the nasopharyngeal mucosa and lung tissue determined by qRT-
 157 PCR (Spearman correlation). (C) Scoring of prevalent histopathology patterns in lungs. Cases

158 are ordered according to duration of disease. (D) Main discrimination of lung pathology
159 according to DAD and pneumonia patterns. Cases are ordered according to alveolar neutrophil
160 counts. (E) Correlation analyses of neutrophil abundance and clinical parameters (Spearman
161 correlation; Mann-Whitney test). (F) Serum C-reactive protein (CRP) and interleukin-6 (IL-6)
162 levels (Mann-Whitney test) in DAD versus pneumonia cases.
163

164 Three cases showed DAD superimposed with acute inflammation and 5 cases showed mainly
165 pneumonia as the dominant pathology, wherein DAD was only focally visible overlaid with
166 dense inflammation. Altogether, 16 cases showed neutrophilic granulocytes present in
167 bronchi, bronchioli or alveoli suggestive of secondary infections. Thus, lung histopathology in
168 lethal covid-19 could be stratified into DAD, DAD superimposed with pneumonia and
169 dominating pneumonia (Figures 2D and S3). Noteworthy, neither disease duration nor viral
170 loads correlated with presence of neutrophils, nor did any other clinical parameter (Figures
171 2E and S6), however, pneumonia cases showed increased IL-6 levels compared to pure DAD
172 cases, whereas CRP levels did not differ between categories (Figure 2F). Other organs showed
173 features of preexisting comorbidities including arteriosclerosis, hypertension and diabetes,
174 especially in the kidneys, wherein SARS-CoV-2 could be detected in tubular epithelia by
175 positive immunohistochemistry (Figure S7). Heart and liver specimens revealed no clear
176 evidence of direct SARS-CoV-2 carriage nor features of myocarditis or hepatitis (Figures S8 and
177 S9). A detailed summary of organ histopathologies is given in the supplementary appendix
178 (Table S6).

179

180 **Lung microbiome alterations and secondary-infections in lethal covid-19**

181 The lung microbiome is altered in DAD and thought to be a relevant factor for the
182 development of secondary infections [9, 10]. RNAseq data from lung tissues was screened for
183 microbial sequences and bacterial (16S rRNA gene) and fungal (internal transcribed spacer,
184 ITS) marker genes were amplified to additionally specify microbial changes. On average

185 6573.33±2552.32 (MW±SD) reads per million (rpm) per sample were not human in RNAseq
186 and likely of microbial origin, of those 2.02±4.00% and 0.03±0.05% could be clearly annotated
187 to specific microbes with different microbial annotation pipelines (Figure 3A). Excluding SARS-
188 CoV-2 reads, which were the dominant microbial component in several cases (range: 0.01 –
189 131218.36 rpm), bacterial sequences were dominant, significantly increased in covid-19 cases
190 with pneumonia compared to DAD and controls. Fungal and viral sequences other than SARS-
191 CoV-2 were also significantly enriched in covid-19 cases with pneumonia (Figure 3B). Number
192 of bacterial reads significantly correlated with neutrophil scores suggesting that their
193 presence is a sign of secondary infections, however, the post-mortem interval did not,
194 precluding a strong influence of post-mortal bacterial overgrowth in our investigation (Figure
195 3C). Bacteria are assumed to be the dominant microbiome component in lungs [11]. Analysis
196 based on the bacterial 16S rRNA gene marker showed that richness was significantly
197 decreased in the DAD and pneumonia cases of covid-19 compared to controls indicating an
198 overall reduced biodiversity (Figure 3D). In contrast, evenness was significantly decreased in
199 the pneumonia group of covid-19 only, suggesting a dominance of certain taxa, possibly
200 representing the agents of secondary infections (pairwise Kruskal-Wallis; *p<0.05,
201 **p<0.005). Principal component analysis (PCA) clearly separated controls from covid-19
202 cases with DAD and cases with pneumonia indicating significantly different bacterial
203 community compositions (Figure 3D). Lung tissues were also cultured for bacteria and fungi
204 and both, covid-19 cases and controls, yielded cultivable microorganisms but in different
205 quantities and taxonomic constellations (Table S7).

214 UniFrac and Bray Curtis distance) clearly separates DAD and pneumonia cases of covid-19
215 from controls (16S rRNA gene). (F) Summary of bacterial, fungal and viral microbes prevalent
216 in covid-19 lungs. Shown are microbes detected by cultivation, RNA and/or DNA sequencing.
217 (G) Dominant pathogens causing secondary infections in covid-19 lungs compared to controls
218 (summary of cultivation and deep sequencing). (H) Microscopic representation (H&E) of
219 bacterial (left, case #16) and fungal (middle, case #18) pathogens in lung tissues. Epstein Barr
220 virus RNA positivity in lung tissue (EBV RNA in-situ hybridization, case #11).
221


222 Finally, we integrated RNAseq, 16S, ITS and culture data to define dominant pathogens, most
223 likely representing the agents of secondary infections and to account for the different samples
224 used for microbial identifications in the light of the patchy disease representations likely
225 impacting the microbial repertoires (Figure S10, Table S8). Dominant pathogens were defined
226 if they were dominant in the RNA and/or DNA data (representing > 10% of microbial reads
227 excluding SARS-CoV-2) and if they also yielded a reasonable culture growth ($\geq 10^4$ cfu/ml).
228 Dominant taxa were typical agents of pulmonary secondary infections like *Staphylococcus*
229 *aureus*, *Enterococcus faecium* or *Klebsiella pneumoniae*, as well as fungi like *Candida* spp. or
230 the mold *Rhizopus microsporus* identified in one case (#18). Often multiple pathogens were
231 found simultaneously indicating polymicrobial infections (e.g. in case #16 wherein *K.*
232 *pneumonia*, *S. aureus* and *C. glabrata* were cultivated in reasonable amounts and were also
233 captured by RNAseq). In addition, 5 covid-19 cases yielded transcripts of Epstein Barr virus
234 (EBV), which were also detectable by RNA *in-situ* hybridization of lung tissues but not in
235 controls (Figure 3H). EBV often emerges due to endogenous reactivation in the context of
236 impaired immunity [12]. Control cases yielded microbial sequences and cultivable microbes in
237 lower quantity and they often belonged to known contaminants like *Lactobacillus* sp. or
238 *Propionibacterium* sp. (Table S8). In summary, the lung microbiome in covid-19 shows a
239 reduced taxonomic richness but harbors a diverse spectrum of bacterial and fungal pathogens
240 typically associated with secondary lung infections. Prominent pathogens like *S. aureus*,
241 *Klebsiella* or *Candida* spp. are also known agents of secondary infection in influenza, SARS and

242 MERS [13, 14]. Notably, secondary infections were rarely detected ante-mortem in our cohort
243 (Table S8). The presence of poly-microbial infections and the relatively high proportion of EBV
244 positivity suggests an overall impaired immunity in covid-19 lungs.

245

246 **The lung metatranscriptome mirrors the major death categories DAD and pneumonia.**

247 Deep RNAseq of lung tissue revealed 4,547 differentially expressed genes between
248 covid-19 cases and controls (adj. $P < 0.05$). Hierarchical clustering indicated depleted (cluster
249 1) or enriched (cluster 2) genes in covid-19 compared to controls (Figure 4A). Pathway analysis
250 indicated impaired central cellular functions within mRNA metabolism, post-translational
251 protein modification, the respiratory chain, VEGFA signaling and extracellular matrix
252 organization in covid-19. Enriched pathways consisted mainly of innate and adaptive immune
253 functions, neutrophil degranulation, cytokine signaling as well as complement activation
254 (Figure 4B). Overall, these data confirm profound and complex transcriptional alterations in
255 covid-19 lung tissue [15-17]. Unsupervised principal components analysis (PCA) of
256 differentially expressed genes clearly separated covid-19 samples on principal component 1
257 (PC1) from controls but also clearly separated pneumonia samples from pure DAD cases
258 (Figure 4C). Comparison of differentially expressed genes between these major death
259 categories indicated that the major discriminator from controls was DAD showing 3862 unique
260 differentially expressed genes (adj. $P < 0.05$ and abs LFC ≥ 0.58) followed by pneumonia with
261 1673 unique differentially expressed genes (Figure 4D). DAD and pneumonia differed by only
262 226 differentially expressed genes. Notably, amongst the top 50 differential expressed genes
263 enriched in pneumonia cases several macrophage markers were evident, including the
264 receptor *ADGRE1* (murine homolog F4/80) as top-hit, the interleukin-1 receptor-associated
265 kinase-like 2 (*IRAK2*) or *PSTPIP2*, which is involved in macrophage polarization (Figure 4E).



266

267 **Figure 4. The lung metatranscriptome mirrors the major death categories DAD and**
 268 **pneumonia.** (A) Hierarchical clustering shows depleted (cluster 1) and enriched (cluster 2)
 269 genes (n=4,547; adj. P<0.05) in lung tissue of covid-19 cases compared to controls. (B) Gen set
 270 enrichment analysis (canonical pathways) of major depleted (top) and enriched (bottom)
 271 pathways in covid-19 lungs. (C) PCA based on differentially expressed genes clearly
 272 discriminates DAD cases and cases with secondary pneumonia of covid-19 from controls. (D)
 273 Venn diagram specifying differentially expressed genes in DAD as the major discriminator
 274 followed by pneumonia (adj. P<0.05, LFC≥0.58). (E) Volcano plot showing the top 25
 275 significantly deregulated genes in secondary pneumonia versus DAD. Several macrophage
 276 genes are increased.

277


278

279 Thus, macrophages seem to be implicated in covid-19 secondary infections. In summary, deep
280 transcriptomic analyses specified multiple dysregulated processes in covid-19, including
281 vascular and coagulation systems, connective tissue remodeling as well as activated immunity
282 and complement [18]. Similar to histopathology, the major discriminator from controls based
283 on gene expression was DAD followed by pneumonia likely mirroring the development of
284 secondary infections on top of ALI caused by the virus.

285

286 **Cellular deconvolution subgroups covid-19 lung pathology.**

287 Cellular compositions were inferred from deep RNAseq data by using xCell [19].
288 Hierarchical clustering based on cellular compositions clearly separated samples into four
289 distinct groups. Group 1 ("control") consisted only of control cases and was related to group
290 2 ("DAD1") consisting of covid-19 cases with pure DAD (in addition to one control case #22).
291 Group 3 ("DAD2") contained also DAD cases, including one sample with the histological
292 category DAD and secondary pneumonia. This group was related to group 4 ("pneumonia")
293 composed of all pneumonia cases, in addition to 3 DAD cases and the two remaining DAD
294 cases with secondary pneumonia (Figure 5A). Noteworthy, neither disease duration nor SARS-
295 CoV-2 loads clearly correlated with a specific grouping. Cell types discriminating these groups
296 showed a specific assembly (Figure 5B). Cluster 1 consisted mainly of vascular and stromal cell
297 types like endothelial cells, pericytes and fibroblasts, enriched in "DAD1" and "DAD2". Top
298 enriched genes in this cluster were certain collagen genes, the vascular transcription factor
299 *sox 18*, the basement membrane protein *laminin-1* or the endothelial protein *stabilin-1* (Figure
300 5C). Cell types of cluster 2 consisted mainly of structural and stromal cells, in addition to
301 certain immune and blood cell types and they were overall reduced in covid-19.



302

303 **Figure 5. Cellular deconvolution stratifies lung pathology sub-groups.** (A) Hierarchical
 304 clustering based on cell-type enrichments derived from xCell analysis indicates a specific
 305 grouping of samples. (B) Scheme indicating cell clusters which discriminate different groups.
 306 (C) Top induced genes in the respective cell clusters determining the specific grouping
 307 (Kruskal-Wallis test).

308

309 Top down-regulated genes included the extracellular matrix proteins *sparc-like 1*, *multimerin-*
310 *1* and *plastin-3* or the cell adhesion molecule *p-selectin* important for the recruitment of
311 leukocytes typically prevalent on activated endothelial cells and platelets (Figure 5C).
312 Together these alterations highlight the vascular and connective tissue changes emerging
313 during DAD development (Figure 2B) [20, 21]. Cell types of cluster 3, which were dominantly
314 induced in "DAD2" and to a lesser extent in "pneumonia" showed enrichment of myeloid
315 (cluster 3a) and epithelial cell types (cluster 3b). Top induced genes in cluster 3a were the
316 myeloid cell specific genes *siglec-1*, *CD11c* and complement factor *C1q*. Top induced genes in
317 cluster 3b consisted of *keratin 6A*, *collagen XVII*, the tyrosine kinase signaling protein *cbl-c* and
318 beta-1,3-N-acetylglucosaminyltransferase 3 (*b3gnt3*), typically expressed in epithelia and also
319 involved in lymphocyte trafficking and homing. Cell types in cluster 4, strongly increased in
320 "pneumonia" consisted of different leukocyte classes including B-, T-cells and (neutrophilic)
321 granulocytes. Top induced genes consisted of the interleukin 8 receptor genes *cxcr1* and *cxcr2*,
322 the chemokine receptor type 2 (*CCR2*), *CEACAM3*, *CD22* (B cell marker), and the cell surface
323 receptors *TREML2* and *FCGR3B*.

324 In summary, cellular deconvolution clearly sub-stratified the major categories DAD and
325 pneumonia of covid-19 lung pathology. Noteworthy, DAD subclustered into two different
326 groups, one showing mainly induction of vascular and stromal cell elements ("DAD1"), the
327 other dominant induction of genes related to myeloid and epithelial cells ("DAD2"), and this
328 subgroup showed more commonalities with the pneumonia group.

329

330 **Macrophages, complement c1q and immune impairment in covid-19 lungs**

331 Myeloid cells including macrophages play a central role in the pathogenesis of DAD
332 [22-24], and bronchioloalveolar lavage fluids (BALF) of patients with severe covid-19 show


333 high proportions of macrophages [15, 25]. We confirmed significantly increased macrophages
334 in covid-19 lungs by CD163 Immunohistochemistry, a M2-type macrophage marker (Figure
335 6A), corroborating a recent proteomic study wherein CD163 was found amongst the most
336 induced proteins in lungs and spleens derived from covid-19 autopsies [18]. Deconvolution
337 indicated both M1- and M2-type macrophages significantly enriched predominantly in
338 "DAD2" whereas monocytes were mainly induced in the "pneumonia" group (Figure 6B).
339 Increased CD163 positive macrophages gathering around virus positive cells were recently
340 shown also in a macaque model of SARS-CoV infection, indicating that infected pneumocytes
341 may lead to macrophage recruitment in coronavirus infections [26].

342 Among the most discriminative genes between DAD subtypes we found complement
343 factor *C1q* dominantly induced in "DAD2" (Figure 5C). Complement activation is implicated in
344 DAD pathogenesis and linked to severe covid-19 [27-29]. Other complement factors showed
345 no discriminative expression pattern between pathological subgroups in our cohort, except
346 certain complement receptors and properdin mainly induced in pneumonia cases (Figure 6C).
347 Western blots generated from protein extracts of lungs confirmed significantly increased C1q
348 (Figure 6D). A major source of C1q are macrophages corroborated also by a recent single-cell
349 transcriptomic analysis of covid-19 lungs (Figure S11) [30, 31] suggesting a strong connection
350 between macrophages and complement C1q in covid-19 [32]. Immunohistochemical analysis
351 of lung tissues with a C1q antibody showed staining of the vasculature, the interstitial and
352 alveolar space but also of alveolar cells including macrophages and pneumocytes, indicating a
353 multifaceted deposition of C1q in the context of covid-19 in our series (Figure 6E).

354

355

356



357

358 **Figure 6. Macrophage and complement C1q induction in covid-19 lungs.** (A)
 359 Immunohistochemical counting of CD163 positive macrophages shows induction in covid-19
 360 compared to controls (Mann-Whitney test). (B) Both M1 and M2 macrophages are specifically
 361 increased in "DAD2" compared to "DAD1" (grouping according to xCell analysis; Kruskal-Wallis
 362 test).

363 and in pneumonia. (D) C1q protein (29 kDa) is significantly increased in covid-19 lung tissue
364 compared to controls (reference human GAPDH; Mann Whitney test). (E) Significant Induction
365 of C1q detected by immunohistochemistry (Mann Whitney test) and different staining
366 patterns in covid-19 lungs; top left & middle: C1q staining of alveolar cells; top right: double
367 immunohistochemistry staining (red: C1q, nuclear black: TTF-1) shows C1q staining of alveolar
368 macrophages; bottom left: intravascular C1q staining; bottom middle: free C1q specific
369 staining of proteinaceous fluid in the alveolar space; bottom right: double
370 immunohistochemistry staining (red: C1q, nuclear black: TTF-1) shows C1q staining of
371 pneumocytes (TTF-1 positive) .
372


373 C1q is the initiating component of the classical complement cascade but exhibits also immune
374 regulatory functions. It induces the development of pro-resolving M2 type macrophages and
375 is involved in the clearance of apoptotic and necrotic cells, which are highly increased in covid-
376 19 lungs [33-35]. In this process C1q binds to cellular break-down products and is subsequently
377 recognized by phagocyte receptors like the leukocyte-associated immunoglobulin-like
378 receptor 1 (LAIR-1; syn.: CD305) conferring uptake and triggering a tolerogenic state in the
379 phagocyte [36, 37]. As shown by a recent single-cell transcriptomics analysis of covid-19 lungs,
380 *LAIR-1* is mainly present in macrophages (Figure S12) [17]. LAIR-1 together with *LILRB4*
381 (leukocyte immunoglobulin-like receptor subfamily B member 4; syn.: *ILT3*) belong to
382 immunoglobulin-like receptors recognizing collagen domains such as present in C1q, thereby
383 inhibiting immune activation [38, 39]. RNAseq confirmed significant induction of *LAIR-1* and
384 *LILRB4* dominantly in "DAD2" followed by "pneumonia" (Figure 7A). Expressions of all 3 *C1q*
385 polypeptide chains (*A*, *B* & *C*) significantly correlated with *LAIR-1* and *LILRB4* expression but
386 not with induced collagens (Figures 7B and S13). This might suggest a functional link between
387 C1q and the immune inhibitory receptors LAIR-1 and LILRB4.

388

389

390

391



392

393 **Figure 7. Signatures of immune-impairment in covid-19 lungs.** (A) The tolerogenic leukocyte
 394 receptors *LAIR-1* and *LILRB4* are mainly induced in "DAD2" and "pneumonia" (Kruskal-Wallis
 395 test). (B) Spearman correlation of RNA expression of *LAIR-1* and *LILRB4* with *C1q* chains and
 396 induced collagen types (Spearman R; $p^* < 0.05$ to $p^{***} < 0.001$). (C) Significant induction of
 397 *TGFβ1* transcription (Kruskal-Wallis test). Protein measurement by immunohistochemistry
 398 and Western blotting does not show a significant difference of covid-19 lungs to controls
 399 (Mann-Whitney test). (D) Strong induction of immune checkpoint inhibitors in covid-19 (order
 400 according to z-score). (E) *LAG3* transcriptional induction (Kruskal-Wallis test) and increased
 401 lymphocyte staining with immunohistochemistry in covid-19 lung tissue (Mann-Whitney test).
 402 (F) Simultaneous transcriptional induction of immune checkpoint inhibitors in covid-19 lungs
 403 compared to controls (Pearson correlation; $p^* < 0.05$, $p^{***} < 0.001$). (E) Hierarchical clustering

404 of immune checkpoint inhibitors of covid-19 cases shows a separate grouping of samples with
405 high viral loads (transcript abundance) versus samples with the histological pneumonia
406 category (clustering: average linkage; distance measure: Pearson).
407

408 Since the development of secondary infections is likely driven by local immune-impairment
409 we screened for other anti-inflammatory markers. TGF- β 1 is a key factor in the development
410 and healing response of ALI and also implicated in covid-19 lung pathology [40, 41]. *TGF- β 1*
411 transcription was significantly increased in covid-19, showing a huge variability, however, TGF-
412 β 1 protein measured by immunohistochemistry and western blotting showed no significant
413 induction compared to controls (Figures 7C and S14). Since several immune and non-immune
414 cell types are able to produce TGF- β 1, the observed variability in expression might reflect the
415 temporal heterogeneity of lung pathologies in our cohort. Induction of certain inhibitory
416 immune-checkpoints is reported in covid-19 [42-46]. We confirmed transcriptional induction
417 of several inhibitory immune-checkpoints in covid-19 lungs (*LAG3*, *PDCD1*, *ADORA2A*, *VSIR*,
418 *CTLA4*, *SIRPA*, *LAIR1*, *SIGLEC9*, *LILRB4*, *SIGLEC7*, *HAVCR2*), whereas some showed no induction
419 (*CD276*, *SP140*, *IDO1*, *KLRG1*, *CD274*) or were even reduced (*GGT1*, *CD80*) compared to
420 controls (Figures 7D and S15). Noteworthy, the top induced inhibitory immune-checkpoint
421 was found to be *LAG3* (lymphocyte-activation gene 3; syn.: CD223), dominantly induced in
422 "DAD2" and "pneumonia" based on RNAseq, which was also confirmed by
423 immunohistochemistry wherein mainly lymphocytes showed strong staining signals (Figures
424 7E and S16). *LAG3* was recently described as a major increased factor in a plasma proteomic
425 study of severe covid-19 [47]. During immune exhaustion multiple inhibitory receptors act
426 often in synergy amplifying immune impairment, like *LAG3* and *PD-1* co-induced during
427 chronic viral infections [48]. We confirmed synergistic induction of several inhibitory immune-
428 checkpoints in covid-19 lungs, which showed a different costimulatory pattern compared to
429 controls (Figure 7F). Interestingly, co-expression patterns discriminated cases with high viral

430 loads (*KLRG1, CTLA4, SP140, CD274, IDO1, LAG3, PDCD1, HAVCR2, CD80*) from samples with
431 pneumonia (*CD276, TGFB1, ADORA2A, LILRB4, LAIR1, VSIR, SIRPA, SIGLEC7, SIGLEC9*)
432 suggesting a divergent pattern of induction of inhibitory immune-checkpoints during the
433 course of covid-19 lung pathology (Figure 7G). In summary, these data highlight that multiple
434 pillars of immune impairment act in severe covid-19, leading to a reduced antimicrobial
435 defense in lungs driving the development of secondary infections. The molecular dissection of
436 cell types and immune inhibitory signals might enable the development of specific measures
437 counteracting this potentially lethal complication.

438

439 Discussion

440 We performed a systematic autopsy study of 20 consecutive covid-19 cases and 14
441 controls to gain unbiased information about lethal disease courses from the early pandemic.
442 Integration of autopsy, cultivation and deep sequencing provided important clues about host
443 and microbial factors involved in the development of secondary infections as a major sequel
444 of lethal covid-19. Thus, our study might serve as a blue-print for a "holistic" autopsy approach
445 tempting to gain relevant pathophysiological insights from a newly emerging disease. Viral
446 genotyping facilitated directly from autopsy material provided epidemiologic clues about
447 transmission and captured already early events of viral genetic adaptation. Noteworthy, a
448 significant proportion of corpses yielded cultivable SARS-CoV-2 indicating that autopsy might
449 facilitate virus spread and that special safety requirements should be applied during post-
450 mortem examinations of covid-19 patients [49]. Our investigation showed that covid-19 lung
451 pathology is multifaceted and that a major discriminator of lethal courses is DAD and the
452 presence of secondary infections. This was evident by histology but also mirrored by the deep
453 transcriptomic analysis and microbiology. Secondary infections are reported to develop in up

454 to 42% of patients with covid-19 [7]. Notably, DAD caused by the virus itself and secondary
455 infections are chronologically divergent and provoke overtly different host reactions.
456 Noteworthy, SARS-CoV-2 infection alone might not trigger prominent neutrophil recruitment
457 to the lung at all and neutrophil signatures found in recent covid-19 studies might likely
458 already indicate secondary infections [15, 18, 31, 50, 51]. Thus, it is important to seek for a
459 proper pre-classification of tissue samples based on histology to omit wrong conclusions in
460 omics-based analyses.

461 The resident lung microbiome is a relevant factor in the pathogenesis of lung infections
462 and reported to be altered in sepsis and DAD [9, 10]. Secondary lung infections are also a
463 complication in influenza, SARS and MERS, wherein bacteria like *S. aureus* or *Klebsiella* spp.
464 and fungi like *Candida* or *Aspergillus* spp. are emerging [13, 14]. Such microbial agents were
465 also prevalent in our cohort. Curiously, the mechanistic understanding why secondary
466 infections develop on top of viral infections is still limited. We could not identify any associated
467 clinical parameter clearly correlated with secondary infections but showed that lung immunity
468 is impaired in covid-19, which might drive these infections. This finding was also underscored
469 by the presence of polymicrobial infections and EBV indicative for a general decreased
470 immunity [12]. Immune exhaustion seems to follow the systemic immune hyperactivation in
471 severe covid-19 and myeloid cells, which are important for the recognition of virus infected
472 cells seem to be key for initiating the proinflammatory response [52, 53]. Recent single-cell
473 transcriptomic studies of covid-19 patients identified myeloid cells as a major induced cell
474 type in BALF specimens with high proportions of proinflammatory macrophages [15, 50].
475 Generally, M1-type macrophages dominate early DAD, whereas later DAD stages show
476 increased M2-types involved in tissue repair with immunosuppressive features [23]. Thus,
477 later (organizing) phases of DAD might be specifically prone to acquire secondary infections.

478 Respiratory failure in covid-19 is linked to strong complement activation [27, 28, 54]. Extensive
479 deposition of complement factors, including C1q, in vessels and epithelial cells of lungs and
480 skin was reported in covid-19 [55, 56]. Notably, the SARS-CoV-2 spike-protein might directly
481 activate complement via the alternative pathway [57]. Complement in covid-19 is currently
482 discussed mainly in the context of endothelial injury and fibrin-clot formation [29]. Our study
483 suggests another pathophysiological role, wherein C1q and macrophages might perpetuate
484 immune impairment. Immune complexes formed by viral antigens and antibodies can activate
485 factor C1 as shown in SARS-CoV infection [58]. C1q is involved in the clearance of apoptotic
486 and necrotic cells by phagocytes, a process termed efferocytosis [59]. Apoptosis and necrosis
487 are prominent in covid-19 lungs [33, 34, 47]. During efferocytosis suppression of
488 overwhelming inflammation is important and phagocytes involved in this process are
489 producing anti-inflammatory cytokines. Therefore, C1q binds to molecules released from
490 apoptotic and necrotic cells (e.g. phosphatidylserine, nucleic acids, etc.) and these complexes
491 are recognized by receptors present on phagocytes, like LAIR-1, conferring uptake and
492 inducing a tolerogenic state [30, 35-37]. Noteworthy, binding of C1q to LAIR-1 on plasmacytoid
493 DCs restricts the production of type I interferons impairing antiviral defense, which also occurs
494 in covid-19 [36, 39]. The "DAD2" subtype in our study shows increased macrophages, C1q and
495 LAIR-1 and might therefore represent cases with a lowered immune tone prone for the
496 development of secondary infections. Overall the progression of early (exudative) DAD into
497 late (fibrotic) DAD indicates healing of ALI characterized by significant connective tissue
498 remodeling and a reduced inflammatory tone [60, 61]. Immune suppressive factors such as
499 TGF- β 1 are known to be involved in this process and also LAIR-1 and LILRB4 recognizing
500 collagens or collagen-like proteins might act anti-inflammatory during this disease phase [39,
501 62-65]. Moreover, the synergistic induction of several tolerogenic factors including inhibitory

502 immune-checkpoints [42-47, 66] and increased (apoptotic) cell death of immune-cells [67, 68]
503 altogether perpetuate immune failure in covid-19.

504 The limitations of our descriptive study are that causalities cannot be directly inferred
505 and that the relatively small cohort cannot show the entire picture of severe covid-19 and
506 associated secondary infections. Varying clinical courses and different comorbidities might
507 also have influenced our findings. In addition, treatment of covid-19 has changed since the
508 early pandemic, thus, current severe courses and developing sequels might also have
509 changed. We also cannot be sure whether the two described forms of DAD might represent
510 just a spectrum of pathophysiological states or are specific pathotypes. Moreover, post-
511 mortem effects like RNA degradation might have introduced additional noise in our
512 investigation. Nevertheless, we found autopsy complemented with microbiology and
513 molecular measures as a powerful tool to gain relevant clues about covid-19 pathophysiology.
514 Importantly, there exists an obvious knowledge gap in the understanding of the molecular
515 mechanisms driving the development of secondary infections on top of in viral lung diseases.
516 This should initiate further studies to understand the molecular pathways in more detail and
517 to unravel chronological phases of immuno-suppression which could also lead to development
518 of rational therapies counteracting this sequel not only in covid-19. For these investigations,
519 autopsy specimens and associated molecular data might serve as a valuable resource.

520

521 **Material and Methods**

522 **Autopsy procedure & specimen collection**

523 Autopsies were performed according to CDC guidelines
524 (<https://www.cdc.gov/coronavirus/2019-ncov/hcp/guidance-postmortem-specimens.html>)
525 and the epidemic response plan of the county of Styria in a BSL-3 facility that has been
526 specifically designed for post-mortem examinations and sample collection [49]. Full autopsies
527 were performed and swabs (eSwab, Copan), tissue and body fluid samples were taken. Tissues
528 were immediately fixed in 10% buffered formalin (for histology) or 2,5% buffered (sodium

529 cacodylate; pH 6.5; Sigma) glutaraldehyde (for electron microscopy), snap frozen in liquid
530 nitrogen or preserved in RNAlater (ThermoFisher) and stored at -80°C until further processing.

531

532 **Histopathology and immunohistochemistry**

533 Formalin-fixed paraffin-embedded (FFPE) tissue specimens were processed and stained
534 according to standard procedures. Stains consisted of hematoxylin & eosin (H&E), periodic
535 acid–Schiff (PAS), chromotrope aniline blue (CAB), sirius red, Gomori, Prussian blue, Giemsa
536 and toluidine blue. Chronic renal changes involving the individual renal compartments were
537 scored according to Sethi et al. [69]. Liver fibrosis was scored according to Ishak et al [70]. The
538 following antibodies were used: Anti-SARS-CoV-2 nucleoprotein (NP) antibody (clone ID: 019,
539 dilution 1:100, rabbit IgG; Sino Biological, Beijing; detection-system: Dako REAL™ EnVision
540 TM HRP rabbit/mouse Dako K5007); CD68 (Ventana anti-CD68 (KP-1) monoclonal mouse 790-
541 2931; detection-system: Ventana Ultra View DAB); TTF1 (Cell marque 343M-96 Clone
542 8G7G3/1 monoclonal mouse 1:200; detection-system: Dako K5007); TGFβ1 (Santacruz
543 polyclonal rabbit AB; clone SC-146 1:50; detection-system: Ventana Ultra View DAB); LAG3
544 (Abcam polyclonal rabbit; clone ab180187 1:5000; detection-system: Dako K5007); C1q (Dako
545 polyclonal rabbit, clone A0136 1:5000; detection-system: Dako K5007); CD163 (Ventana
546 monoclonal mouse, clone MRQ-26 1:50; detection-system: Ventana Ultra View DAB). RNA in-
547 situ hybridization for EBV was performed with the Inform EBER Epstein Barr Virus early RNA
548 kit (Ventana 800-2824) and the detection-system ISH invers blue (Ventana).

549

550 **Scoring of histological lung features**

551 From each case multiple specimens from each lobe were taken to account for variations in
552 disease representation (at least 2 specimens per lobe corresponding to 10 specimens per case
553 at least, mean: 13, range: 10-21) and assessed for histopathological features. Features were
554 grouped according to (a) early (exudative) and (b) late (fibrotic) DAD as well as (c) general
555 cellular and tissue reactions in pulmonary pathology and DAD development [21] and consisted
556 of: Interstitial edema/thickening of the alveolo-capillary membranes (non-fibrotic); alveolar
557 edema; hyaline membranes; intra-alveolar (loose) fibrin; scaled of pneumocytes; intra-
558 alveolar proliferation of pneumocytes; alveolar septal fibrosis (early stage organizing DAD);
559 alveolar septal fibrosis (end stage organizing DAD); bronchialisation; squamous metaplasia;
560 virus induced cellular changes in pneumocytes and/or alveolar macrophages; alveolar
561 hemorrhage; interstitial hemorrhage; interstitial hemosiderin (free); alveolar hemosiderin
562 (siderophages); fibrin thrombi (capillaries); fibrin thrombi (larger vessels); vascular remodeling
563 (increased density, vascular fissures); intra-alveolar macrophage accumulation; lymphocytes
564 (within alveolo-capillary membranes); lymphocytes (within interstitial space); intra-alveolar
565 (fibro-) cellular infiltrate; lymphocytes (alveolar); megakaryocytes (capillaries); alveolar
566 neutrophils; bronchial neutrophils; a 4-grade scoring system was used to describe the severity
567 of the different pathological features. Score 0 (feature absent), score 1 (feature present in
568 ≤33%), score 2 (feature present in ≤66%), score 3 (feature present in > 66%). Scores per
569 slides were summed up and a final score (mean value) was calculated.

570

571 **Microbial culture and identification**

572 Native lung tissues were transferred into mixing vessels (ProbeAX; AxonLab) containing 5 ml
573 of physiological saline and were homogenized using a dispersion instrument (ULTRA-TURRAX®
574 Tube Drive; AxonLab). The homogenates were inoculated (0.1 ml aliquots) onto aerobic blood
575 agar, MacConkey agar, chocolate agar, and anaerobic blood agar (BD Diagnostic) and into
576 thioglycollate broth (Oxoid). Plates were incubated at 35°C and 37°C aerobically, in an

577 atmosphere containing 5 % carbon dioxide and anaerobically (Genbox anaer, bioMérieux) for
578 up to 14 days, respectively. Cloudy thioglycollate broths were sub-cultured on plates. Colonies
579 were identified using matrix-assisted-laser-desorption-ionization time-of-flight mass-
580 spectrometry (MALDI-TOF MS; Vitek[®] MS, bioMérieux or MALDI Biotyper[™], Bruker) or 16S
581 rRNA gene sequencing [71].

582

583 **Virus isolation**

584 Lung tissues and swabs from lung parenchyma were used for cultivation of SARS-CoV-2 (Table
585 S3). After mechanical disruption samples were frozen (-80°C) and thawed (37°C) twice to
586 increase cell lysis and viral release. 2mL OptiPro SFM medium (Gibco) with 4mM L-Glutamine
587 (Gibco) and 1% penicillin-streptomycin (10,000 U/ml; Gibco) were added to the samples. After
588 centrifugation (10 min., 1500 rcf) the supernatants were filtered through a 0.45µm membrane
589 filter (Millipore) and inoculated on Vero CCL-81 cells with OptiPro SFM medium with 4mM L-
590 Glutamine and 1% penicillin-streptomycin in T25 flasks (ThermoFisher). After 3-4 days
591 incubation at 37°C and 5% CO₂, the whole cells were mechanically detached with cell scrapers
592 and passaged including the supernatant on to new Vero CCL-81 cells growing in T75 flasks
593 (ThermoFisher). After 1 week the cells were harvested and supernatants were stored after
594 centrifugation (10min., 1500 rcf) at -80°C. Viral load was determined by qRT-PCR as described
595 below.

596

597 **RNA extraction**

598 Samples consisted of swabs (eSWAB, Copan), tissues and body fluids, the latter were collected
599 with sterile syringes. Fresh tissues were sampled directly into Magna Lyser Green Beads tubes
600 (03358941001, Roche) pre-filled with 400µl lysis buffer. Tissues were homogenized with a
601 MagnaLyser (Roche) instrument using 6500 rpm for 30 sec. and 3 repetitions. RNA was
602 extracted from 200µl eSwab solution, 200µl liquid sample or tissue homogenate using the
603 Maxwell 16 LEV simplyRNA Blood Kit (AS1310, Promega) according to the manufacturer's
604 instructions. RNAs from VeroE6 cell cultures were isolated by using the QIAamp Viral RNA Mini
605 Kit (Qiagen) without addition of carrier RNA and transcribed into cDNA with the High-Capacity
606 cDNA Reverse Transcription Kit with RNase Inhibitor (Applied Biosystems) according to
607 manufacturer's instructions.

608

609 **SARS-CoV-2 quantitative RT-PCR**

610 qRT-PCR was performed using a RdRP gene assay and with a probe specific to SARS-CoV-2
611 [72]. Briefly, primers, probes and 5µl of RNA were added to 10µl of SuperScript III One-Step
612 RT-PCR System with Platinum Taq High Fidelity DNA Polymerase mastermix (ThermoFisher).
613 PCR was performed on a Quantstudio 7 instrument (ThermoFisher) with the following cycling
614 conditions: 55°C for 15 min, 95°C for 3 min; 45 cycles consisting of 95°C for 15sec and 58°C for
615 30sec. Amplification data was downloaded and processed using the qpcR package of the R
616 project (<https://www.r-project.org/>). Amplification efficiency plots were visually inspected
617 and Cp2D (cycle peak of second derivative) values were calculated for samples with valid
618 amplification curves. Plots were generated with R using the reshape, tidyverse and ggplot
619 packages. qRT-PCR of virus cultures employed primer sets recommended by the CDC detecting
620 three different regions of the viral nucleocapsid (2019-nCoV N1-F 5'-GAC CCC AAA ATC AGC
621 GAA AT-3', 2019-nCoV,_N1-R 5'-TCT GGT TAC TGC CAG TTG AAT CTG-3'; 2019-nCoV_N2-F 5'-
622 TTA CAA ACA TTG GCC GCA AA-3', 2019-nCoV_N2-R 5'-GCG CGA CAT TCC GAA GAA-3'; 2019-
623 nCoV_N3-F 5'-GGG AGC CTT GAA TAC ACC AAA A-3', 2019-nCoV_N3-R 5'-TGT AGC ACG ATT
624 GCA GCA TTG-3') and human RNase P as a control (2019-nCoV_RP-F 5'-AGA TTT GGA CCT GCG

625 AGC G-3', 2019-CoV_RP-R 5'-GAG CGG CTG TCT CCA CAA GT-3') or GAPDH (GAPDH_f 5'-
626 CCTCCACCTTTGACGCT-3', GAPDH_r 5'-TTGCTGTAGCCAAATTCGTT-3') as control. PCR was
627 performed with the SYBR Green PCR Mastermix (Applied Biosystems) on a Quantstudio 7
628 instrument (ThermoFisher) with the following cycling conditions: 25°C for 2 min, 50°C for 15
629 min, 95°C for 10min, 45 cycles consisting of 95°C for 3sec and 55°C for 30 sec.

630

631 **Viral genome sequencing**

632 PCR primers spanning the whole genome of SARS-CoV-2 were designed yielding in about 2kb
633 amplicons (Table S9). 2.5µl of RNA were used in three separate RT-PCR reactions as described
634 above with oligonucleotide primers at 400nM concentration with the following cycling
635 conditions: 55°C for 15 min, 95°C for 3 min; 35 cycles consisting of 95°C for 15 sec and 57°C
636 for 3 min; final extension at 72°C for 10 min. PCR products were combined and purified by
637 incubation with 1.8X Ampure XT beads (Beckman Coulter) followed by two washes with 75%
638 ethanol and elution in 30µl water. Amplicons were fragmented to 150-250bp length and Ion
639 Torrent barcode and sequencing adapters were ligated to the fragments using the NEBNext
640 Fast DNA Fragmentation & Library Prep Set for Ion Torren kit (New England Biolabs) according
641 to the manufacturer's recommendations. Libraries were sequenced on an Ion Torrent S5XL
642 instrument using a 540 Chip Kit and the 200bp sequencing kit (ThermoFisher). Sequences were
643 aligned to the SARS-CoV-2 reference genome (acc. no.: NC_045512.2) using TMAP (v5.10.11)
644 and variants were called with the Torrent Variant Caller (v5.10-12). All called variants were
645 visually inspected and consensus sequences of the viral genomes were generated with
646 bcftools (v1.3.1). Consensus sequences were aligned using clustalw (v2.1), guide trees were
647 visualized in figtree (v1.4.4) and final adjustments were made with IncScape (v0.92). SARS-
648 CoV-2 genomes from our study were uploaded and analyzed with the GISAID SARS-CoV-2
649 (hCoV-19) database which can be accessed via [https://www.gisaid.org/epiflu-](https://www.gisaid.org/epiflu-applications/next-hcov-19-app/)
650 [applications/next-hcov-19-app/](https://www.gisaid.org/epiflu-applications/next-hcov-19-app/) [73, 74].

651

652 **RNA sequencing**

653 Libraries for RNA sequencing (RNAseq) from lung tissues (19 covid-19 cases #2-#20 and 7
654 control cases #21, #23-#28) were prepped with the KAPA RNA HyperPrep Kit with RiboErase
655 (HMR) for Illumina® platforms (KAPABIOSYSTEMS) according to the manufacturers protocol.
656 Slight modifications from the protocol consisted of a fragmentation step at 65°C for 1min, 12
657 cycles of PCR, as well as an additional bead cleanup at the end of the prep. Libraries were
658 pooled in two pools of 13 samples each by concentration measured with Qubit
659 (ThermoFisher), followed by a bead-cleanup step and an additional QC with Qubit
660 (ThermoFisher) and BioAnalyzer (Agilent). Sequences were resolved on a NovaSeq 6000
661 Sequencer (Illumina) with a standard paired-end protocol. RNAseq data were aligned to the
662 human reference genome using STAR [75] (GRCh38 assembly, Ensembl V99 gene models) in
663 2-pass mode with the following parameters: -sjdbOverhang 100 -outFilterMultimapNmax 20
664 -outFilterMismatchNoverLmax 0.05 -outFilterScoreMin 0 -outFilterScoreMinOverLread 0 -
665 -outSJfilterReads Unique -outSJfilterOverhangMin 20 15 15 15 15 -outSJfilterCountUniqueMin
666 3 3 3 3 -outSJfilterCountTotalMin 3 3 3 3 -outSJfilterDistToOtherSJmin 0 0 0 0 --
667 -outSJfilterIntronMaxVsReadN 100000 -alignIntronMin 20 -alignIntronMax 100000 --
668 -alignMatesGapMax 100000 -alignSJoverhangMin 12 -alignSJstitchMismatchNmax 5 -1 5 5 -
669 -alignSJDBoverhangMin 7 -alignSplicedMateMapLmin 0 -alignSplicedMateMapLminOverLmate
670 0.5 -limitSjdbInsertNsj 5000000 -clip3pAdapterMMp 0.5 -outSAMmultNmax 1 -
671 -outSAMmapqUnique 60 -outFilterType BySJout -outSAMunmapped Within -outWigType
672 bedGraph -outReadsUnmapped None SortedByCoordinate -outSAMattrIHstart 1 -

673 twopassMode Basic -chimSegmentMin 8 -chimOutType Junctions WithinBAM SoftClip -
674 chimScoreMin 1 -chimScoreDropMax 20 -chimJunctionOverhangMin 8 -
675 chimSegmentReadGapMax 3 -quantMode GeneCounts -outSAMstrandField intronMotif -
676 outFilterIntronStrands None -chimMainSegmentMultNmax 2 -outSAMattributes NH HI AS nM
677 NM MD jM jI XS ch. Alignment to the virus genome reference NC_045512.2 was performed
678 using bowtie2-2.4.1 [76] on all reads that did not map to the human genome. Read counts on
679 plus-/minus-strand were counted using custom python scripts. Exact positioning of the reads
680 on plus-/minus-strand was done splitting the bam files aligned to NC_045512.2 using samtools
681 -f 0x10 and samtools -F 0x10 (v0.1.19-44428cd) and bedtools genomecov -ibam BAM
682 NC_045512.2 -d (bedtools v2.17.0).

683

684 **RNA profiling**

685 Gene counts were determined using HTSeq (v0.12.4) and normalized as fragments per
686 kilobase per million (FPKM) after TMM correction. Gene set variation analysis (GSVA) was
687 performed against a set of immune signatures with xCell [19] and means were calculated per
688 cell type using custom R-scripts. Graphs and analyses were generated using R-3.6.0.
689 Differential gene expression was conducted using edgeR
690 (<https://doi.org/doi:10.18129/B9.bioc.edgeR>) [77]. Differentially expressed genes were
691 selected with FDR<0.05, logCPM>1, and FPKM>1 in at least 5 samples. Clustering of
692 differentially expressed genes was performed using hclust hierarchical clustering and
693 subsequent cutting of the gene tree at R function cutree with h=0.25. Gene set enrichment
694 analysis for clusters was done using the online tool ([https://www.gsea-
695 msigdb.org/gsea/msigdb/annotate.jsp](https://www.gsea-msigdb.org/gsea/msigdb/annotate.jsp)) [78] for canonical pathways and FDR<0.05.

696

697 **Single cell transcriptomic metanalysis**

698 Selected genes from single-cell transcriptomic metadata from Xu et al [31] and Delorey et al
699 [17] were analyzed with the single-cell atlas database SCovid [79].

700

701 **Microbiome analysis based on RNAseq**

702 Microbiome analysis was performed with the following steps using all reads from STAR
703 alignment not mapping to the human reference: quality filtering using fastx -q 30 -p 26 -Q33
704 (v0.0.13, http://hannonlab.cshl.edu/fastx_toolkit/), cleaning of the fasta file using seqclean-
705 x86_64 -N -M -A (<https://sourceforge.net/projects/seqclean/>), realigning to the human
706 reference using blastn against all databases and removal of all reads with 94% similarity.
707 Remaining reads were annotated using MetaPhlan2 (v2.6.0) [80] and Pathseq (GATK v4.1.0.0)
708 [81] with default settings.

709

710 **Microbiome analysis based on the 16S rRNA gene and internal transcribed spacers (ITS)**

711 Bacterial (16S rRNA gene) and fungal (ITS) microbiome analysis from lung tissue was done
712 from FFPE samples which enabled us to preselect samples based on histology showing
713 unambiguous pathology (i.e. DAD vs. pneumonia). DNA was extracted from FFPE tissues using
714 the Maxwell 16 Tissue DNA Purification Kit (Promega). DNA concentration was measured by
715 Picogreen fluorescence. The variable V1-V2 region of the bacterial 16S rRNA gene was
716 amplified with PCR from 50ng DNA using oligonucleotide primers 16s_515_S3_fwd: 5'-
717 TGCCAGCAGCCGCGTAA-3' and 16s_806_S2_rev: 5'-GGACTACCAGGGTATCTAAT-3'. This 16S
718 rDNA region was chosen since it gives robust taxonomic classification and has been shown to
719 be suitable for community clustering. Likewise, fungal ITS sequence was amplified with
720 primers ITS1 5'-TCCGTAGGTGAACCTGCGG-3' and ITS2 5'-GCTGCGTTCTTCATCGATGC-3'. DNA

721 was amplified with the 16s Complete PCR Mastermix Kit (Molzym). The first PCR reaction
722 product was subjected to a second round of PCR with primers fusing the 16s/ITS primer
723 sequence to the A and P adapters necessary for Ion Torrent sequencing while additionally
724 including a molecular barcode sequence to allow multiplexing of up to 96 samples
725 simultaneously. PCR products were subjected to agarose gel electrophoresis and the band of
726 the expected length (330nt) was excised from the gel and purified using the QiaQuick (Qiagen)
727 gel extraction system. DNA concentration of the final PCR product was measured by Picogreen
728 fluorescence. Amplicons from up to 60 samples were pooled equimolarly and sequencing was
729 performed on Ion Torrent XL benchtop sequencer using the Ion 400BP Sequencing chemistry
730 (all reagents from ThermoFisher). Sequences were split by barcode and transferred to the
731 Torrent suite server.

732 Raw bam-files comprised of single-end reads generated by NGS, were converted from
733 bam files to fastq.gz files by using samtools (<http://www.htslib.org/>). Quality control and
734 preprocessing of sequences was performed using FastQC (version 0.7), MultiQC (version 1.7)
735 and trimmomatic (version 0.36.5) using following parameters: LEADING:3 TRAILING:3
736 SLIDINGWINDOW:4:15 MINLEN:200. Sequence processing and microbiome analysis was
737 performed using QIIME2 (version 2020.6) [82]. After quality filtering all samples with less than
738 9833 reads/samples were excluded from downstream analysis. In concordance with RNA-Seq
739 analysis Covid-19 was excluded for sub-analysis (Cause of Death: Myocardial Infarction),
740 resulting in 18 Covid and 12 control samples for 16S analysis (Average frequency: 28201.7
741 reads/sample). For ITS analysis only 1 sample showed more than 9833 reads/per sample
742 (Covid-19: 10272 reads). All other samples showed no clear ITS signal with a sequencing depth
743 of maximum 219 reads per sample. Denoising, dereplication and chimera filtering of single-
744 end reads were performed using DADA2 (denoise-pyro) [83]. 16S-based analysis was
745 performed with the latest SILVA 138 taxonomy and the Naive Bayes classifier trained on Silva
746 138 99% OTUs full-length sequences. For ITS-based analysis a classifier was trained on the
747 UNITE reference database (ver8-99-classifier; 04.02.2020) according to John Quensen
748 ([http://john-quensen.com/tutorials/training-the-qiime2-classifier-with-unite-its-reference-
749 sequences/](http://john-quensen.com/tutorials/training-the-qiime2-classifier-with-unite-its-reference-sequences/); assessed 20/08/2020). Differences in microbial composition between groups
750 were tested with implemented QIIME2 plugins using PERMANOVA ($p < 0.05$, qiime diversity
751 beta-group-significance: Bray-Curtis, Jaccard, Unweighted UniFrac, Weighted UniFrac) and
752 Kruskal-Wallis ($p < 0.05$, qiime diversity alpha-group-significance: Observed features, Shannon,
753 Evenness, Faith PD). For metagenomic biomarker discovery taxonomic feature-tables were
754 introduced to LEfSe (linear discriminant analysis effect size) method (Galaxy version 1.0;
755 $p < 0.05$, LDA > 2, All-against-all) [84]. Plots were generated with R (version 3.6.2)⁶ in RStudio
756 (1.1.463)⁷ using following packages: tidyverse (1.3.0)⁸, qiime2r (0.99.6)⁹, ggplot2 (3.3.3)¹⁰,
757 dplyr (1.0.6)¹¹ and ggpubr (0.4.0.999)¹² and GraphPad Prism. The graphical abstract was
758 created with BioRender (www.BioRender.com).

759

760 **Protein isolation and western blot**

761 Proteins from lung tissues were extracted with TRIzol[®] (ThermoFisher) according to the
762 supplier's protocol. Briefly, tissue homogenates were subjected to phase separation wherein
763 the organic phase containing the protein was further processed. Four volumes of ice-cold
764 acetone were added to the organic phase and the mixture was incubated at -20°C overnight,
765 followed by a centrifugation step (13000 rpm) at 4°C for 15 min. The supernatant was
766 discarded and the pellets were dried at 60°C for 60 min. Subsequently 100 µl RIPA buffer
767 (Sigma) containing protease inhibitors and phosphatase (0.1 mM Pefabloc, 1 mM DTT, 1X
768 cOmplete[™] Mini, 1X PhosSTOP[™]) and 1 % SDS (Roche) were added and the mixture

769 incubated at 65°C for 90 min. Supernatants were transferred to a new Eppendorf tube and
770 100 µl 8M urea in 0.05M Tris (pH 8,5) and 1% SDS were added and incubated at 55°C for 30
771 min. Corresponding supernatants and pellets were pooled and transferred to 2 ml MagNA
772 Lyser tubes (Roche) with ceramic beads and homogenized 2 times at 6500 rpm for 20 sec.
773 Samples were incubated on ice for 10 min and subsequently centrifugated with 13000 rpm at
774 4°C for 15 min. Supernatants were transferred to new Eppendorf tubes. For western blotting
775 proteins were mixed with 4X Laemmli buffer (Bio-Rad) and incubated for 10 min at 95°C and
776 then loaded onto 11% (v/v) SDS-PAGE gels (Amersham) and electrophoresed at 80 mA for 2 h
777 and subsequently transferred onto nitrocellulose membranes (Amersham). Blotting efficiency
778 was determined with Ponceau staining (Ponceau S solution, Sigma). Non-specific binding was
779 blocked with 5% (w/v) non-fat dry milk (Bio-Rad) in TRIS-buffered saline and 0.1% (v/v) Tween
780 20 (Merck) for 1h. Subsequently, the membranes were incubated with antibodies against C1q
781 (Dako Denmark A/S 1:5000), TGFβ1 (Cell Signaling Technology, 1:1000), and GAPDH (Cell
782 Signaling Technology, 1:1000) overnight at 4°C. Thereafter, membranes were washed and
783 incubated with the appropriate HRP-conjugated secondary antibody (Amersham, ECL Anti-
784 Rabbit IgG, 1:5000). Immunolabeling was detected using ECL Select Western Blot Reagent
785 (Amersham) and visualized with the ImageQuant™ LAS 500 (Amersham). GAPDH was used as
786 loading control to determine protein abundance and band density was quantified and
787 compared by using ImageJ.

788

789 **Ethics statement**

790 The study was approved by the ethics committee of the Medical University of Graz (EK-
791 number: 32–362 ex 19/20).

792

793 **Data availability**

794 The sequencing data has been deposited in ENA under the acc. no. PRJEB45873.

795

796 **Acknowledgements**

797 We are grateful to Tanja V. Mascher, Birgit Gangl, Margit Gogg-Kamerer, Iris Kufferath, Sylvia
798 Eidenhammer, Christine Langner, Stella Wolfgruber, Daniela Pabst, Helmut Donnerer and
799 Lajos Redecsi for their technical assistance.

800

801 **Funding**

802 Supported from the Medical university of Graz and the Austrian Science fund (FWF, DK-MOLIN
803 W1241). The design of the BSL-3 laboratory used for autopsy of covid-19 cases was supported
804 by the EU-funded program "European Research Infrastructure for Highly Pathogenic Agents"
805 (ERINHA-Advance, Grant agreement 824061).

806

807 **Author contributions**

808 Conceptualization and methodology, MZ, GG, KK, PR, KZ. Investigation and formal analysis,
809 MZ, KK, PW, PR, MS, MN, SE, LM-M, GK, ML, AB, EL, AT, EW, SS, M-JP, F-RV, CL, BJ, LO, GG.
810 Resources, KZ, PR, GG, BT, HL. Writing of original draft GG. Writing, review and editing, all
811 authors. Funding acquisition, KZ, GG, HL. Supervision, GG, PR, KZ. All authors have read and
812 agreed to the published version of the manuscript.

813

814

815 References

- 816 1. Hou, Y.J., et al., *SARS-CoV-2 Reverse Genetics Reveals a Variable Infection Gradient in*
817 *the Respiratory Tract*. Cell, 2020. **182**(2): p. 429-446 e14.
- 818 2. Ramlall, V., et al., *Immune complement and coagulation dysfunction in adverse*
819 *outcomes of SARS-CoV-2 infection*. Nat Med, 2020. **26**(10): p. 1609-1615.
- 820 3. Lowery, S.A., A. Sariol, and S. Perlman, *Innate immune and inflammatory responses*
821 *to SARS-CoV-2: Implications for COVID-19*. Cell Host Microbe, 2021. **29**(7): p. 1052-
822 1062.
- 823 4. Blanco-Melo, D., et al., *Imbalanced Host Response to SARS-CoV-2 Drives Development*
824 *of COVID-19*. Cell, 2020. **181**(5): p. 1036-1045 e9.
- 825 5. Wang, T., et al., *Single-cell RNA sequencing reveals the sustained immune cell*
826 *dysfunction in the pathogenesis of sepsis secondary to bacterial pneumonia*.
827 Genomics, 2021. **113**(3): p. 1219-1233.
- 828 6. Roquilly, A., et al., *Alveolar macrophages are epigenetically altered after*
829 *inflammation, leading to long-term lung immunoparalysis*. Nat Immunol, 2020. **21**(6):
830 p. 636-648.
- 831 7. Buehler, P.K., et al., *Bacterial pulmonary superinfections are associated with longer*
832 *duration of ventilation in critically ill COVID-19 patients*. Cell Rep Med, 2021. **2**(4): p.
833 100229.
- 834 8. Hou, Y.J., et al., *SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and*
835 *transmission in vivo*. Science, 2020. **370**(6523): p. 1464-1468.
- 836 9. Luyt, C.E., et al., *Pulmonary infections complicating ARDS*. Intensive Care Med, 2020.
837 **46**(12): p. 2168-2183.
- 838 10. Dickson, R.P., et al., *Enrichment of the lung microbiome with gut bacteria in sepsis*
839 *and the acute respiratory distress syndrome*. Nat Microbiol, 2016. **1**(10): p. 16113.
- 840 11. Huffnagle, G.B., R.P. Dickson, and N.W. Lukacs, *The respiratory tract microbiome and*
841 *lung inflammation: a two-way street*. Mucosal Immunol, 2017. **10**(2): p. 299-306.
- 842 12. Tangye, S.G., U. Palendira, and E.S. Edwards, *Human immunity against EBV-lessons*
843 *from the clinic*. J Exp Med, 2017. **214**(2): p. 269-283.
- 844 13. Morens, D.M., J.K. Taubenberger, and A.S. Fauci, *Predominant role of bacterial*
845 *pneumonia as a cause of death in pandemic influenza: implications for pandemic*
846 *influenza preparedness*. J Infect Dis, 2008. **198**(7): p. 962-70.
- 847 14. Klein, E.Y., et al., *The frequency of influenza and bacterial coinfection: a systematic*
848 *review and meta-analysis*. Influenza Other Respir Viruses, 2016. **10**(5): p. 394-403.
- 849 15. Liao, M., et al., *Single-cell landscape of bronchoalveolar immune cells in patients with*
850 *COVID-19*. Nat Med, 2020. **26**(6): p. 842-844.
- 851 16. Wu, M., et al., *Transcriptional and proteomic insights into the host response in fatal*
852 *COVID-19 cases*. Proc Natl Acad Sci U S A, 2020. **117**(45): p. 28336-28343.
- 853 17. Delorey, T.M., et al., *COVID-19 tissue atlases reveal SARS-CoV-2 pathology and*
854 *cellular targets*. Nature, 2021. **595**(7865): p. 107-113.
- 855 18. Nie, X., et al., *Multi-organ proteomic landscape of COVID-19 autopsies*. Cell, 2021.
856 **184**(3): p. 775-791 e14.
- 857 19. Aran, D., Z. Hu, and A.J. Butte, *xCell: digitally portraying the tissue cellular*
858 *heterogeneity landscape*. Genome Biol, 2017. **18**(1): p. 220.
- 859 20. Ackermann, M., et al., *Pulmonary Vascular Endothelialitis, Thrombosis, and*
860 *Angiogenesis in Covid-19*. N Engl J Med, 2020. **383**(2): p. 120-128.

- 861 21. Hughes, K.T. and M.B. Beasley, *Pulmonary Manifestations of Acute Lung Injury: More*
862 *Than Just Diffuse Alveolar Damage*. Arch Pathol Lab Med, 2017. **141**(7): p. 916-922.
- 863 22. Chen, X., et al., *Macrophage polarization and its role in the pathogenesis of acute*
864 *lung injury/acute respiratory distress syndrome*. Inflamm Res, 2020. **69**(9): p. 883-
865 895.
- 866 23. Huang, X., et al., *The Role of Macrophages in the Pathogenesis of ALI/ARDS*.
867 *Mediators Inflamm*, 2018. **2018**: p. 1264913.
- 868 24. Fan, E.K.Y. and J. Fan, *Regulation of alveolar macrophage death in acute lung*
869 *inflammation*. Respir Res, 2018. **19**(1): p. 50.
- 870 25. Wang, C., et al., *Alveolar macrophage dysfunction and cytokine storm in the*
871 *pathogenesis of two severe COVID-19 patients*. EBioMedicine, 2020. **57**: p. 102833.
- 872 26. Liu, L., et al., *Anti-spike IgG causes severe acute lung injury by skewing macrophage*
873 *responses during acute SARS-CoV infection*. JCI Insight, 2019. **4**(4).
- 874 27. Holter, J.C., et al., *Systemic complement activation is associated with respiratory*
875 *failure in COVID-19 hospitalized patients*. Proc Natl Acad Sci U S A, 2020. **117**(40): p.
876 25018-25025.
- 877 28. Java, A., et al., *The complement system in COVID-19: friend and foe?* JCI Insight, 2020.
878 **5**(15).
- 879 29. Perico, L., et al., *Immunity, endothelial injury and complement-induced coagulopathy*
880 *in COVID-19*. Nat Rev Nephrol, 2021. **17**(1): p. 46-64.
- 881 30. Lu, J.H., et al., *The classical and regulatory functions of C1q in immunity and*
882 *autoimmunity*. Cell Mol Immunol, 2008. **5**(1): p. 9-21.
- 883 31. Xu, G., et al., *The differential immune responses to COVID-19 in peripheral and lung*
884 *revealed by single-cell RNA sequencing*. Cell Discov, 2020. **6**: p. 73.
- 885 32. Carvelli, J., et al., *Association of COVID-19 inflammation with activation of the C5a-*
886 *C5aR1 axis*. Nature, 2020. **588**(7836): p. 146-150.
- 887 33. Li, S., et al., *SARS-CoV-2 triggers inflammatory responses and cell death through*
888 *caspase-8 activation*. Signal Transduct Target Ther, 2020. **5**(1): p. 235.
- 889 34. Mulay, A., et al., *SARS-CoV-2 infection of primary human lung epithelium for COVID-*
890 *19 modeling and drug discovery*. Cell Rep, 2021. **35**(5): p. 109055.
- 891 35. Bohlsion, S.S., et al., *Complement, c1q, and c1q-related molecules regulate*
892 *macrophage polarization*. Front Immunol, 2014. **5**: p. 402.
- 893 36. Son, M., B. Diamond, and F. Santiago-Schwarz, *Fundamental role of C1q in*
894 *autoimmunity and inflammation*. Immunol Res, 2015. **63**(1-3): p. 101-6.
- 895 37. Thielens, N.M., et al., *C1q: A fresh look upon an old molecule*. Mol Immunol, 2017. **89**:
896 p. 73-83.
- 897 38. Lebbink, R.J., et al., *Collagens are functional, high affinity ligands for the inhibitory*
898 *immune receptor LAIR-1*. J Exp Med, 2006. **203**(6): p. 1419-25.
- 899 39. Son, M., et al., *C1q limits dendritic cell differentiation and activation by engaging*
900 *LAIR-1*. Proc Natl Acad Sci U S A, 2012. **109**(46): p. E3160-7.
- 901 40. Peters, D.M., et al., *TGF-beta directs trafficking of the epithelial sodium channel ENaC*
902 *which has implications for ion and fluid transport in acute lung injury*. Proc Natl Acad
903 Sci U S A, 2014. **111**(3): p. E374-83.
- 904 41. Vaz de Paula, C.B., et al., *COVID-19: Immunohistochemical Analysis of TGF-beta*
905 *Signaling Pathways in Pulmonary Fibrosis*. Int J Mol Sci, 2021. **23**(1).
- 906 42. Files, J.K., et al., *Sustained cellular immune dysregulation in individuals recovering*
907 *from SARS-CoV-2 infection*. J Clin Invest, 2021. **131**(1).


- 908 43. Jeannet, R., et al., *Severe COVID-19 is associated with deep and sustained*
909 *multifaceted cellular immunosuppression*. Intensive Care Med, 2020. **46**(9): p. 1769-
910 1771.
- 911 44. Li, M., et al., *Elevated Exhaustion Levels of NK and CD8(+) T Cells as Indicators for*
912 *Progression and Prognosis of COVID-19 Disease*. Front Immunol, 2020. **11**: p. 580237.
- 913 45. Bobcakova, A., et al., *Immune Profile in Patients With COVID-19: Lymphocytes*
914 *Exhaustion Markers in Relationship to Clinical Outcome*. Front Cell Infect Microbiol,
915 2021. **11**: p. 646688.
- 916 46. Diao, B., et al., *Reduction and Functional Exhaustion of T Cells in Patients With*
917 *Coronavirus Disease 2019 (COVID-19)*. Front Immunol, 2020. **11**: p. 827.
- 918 47. Filbin, M.R., et al., *Longitudinal proteomic analysis of severe COVID-19 reveals*
919 *survival-associated signatures, tissue-specific cell death, and cell-cell interactions*. Cell
920 Rep Med, 2021. **2**(5): p. 100287.
- 921 48. Blackburn, S.D., et al., *Coregulation of CD8+ T cell exhaustion by multiple inhibitory*
922 *receptors during chronic viral infection*. Nat Immunol, 2009. **10**(1): p. 29-37.
- 923 49. Loibner, M., et al., *Biosafety Requirements for Autopsies of Patients with COVID-19:*
924 *Example of a BSL-3 Autopsy Facility Designed for Highly Pathogenic Agents*.
925 Pathobiology, 2021. **88**(1): p. 37-45.
- 926 50. Melms, J.C., et al., *A molecular single-cell lung atlas of lethal COVID-19*. Nature, 2021.
927 **595**(7865): p. 114-119.
- 928 51. Wauters, E., et al., *Discriminating mild from critical COVID-19 by innate and adaptive*
929 *immune single-cell profiling of bronchoalveolar lavages*. Cell Res, 2021. **31**(3): p. 272-
930 290.
- 931 52. Merad, M. and J.C. Martin, *Pathological inflammation in patients with COVID-19: a*
932 *key role for monocytes and macrophages*. Nat Rev Immunol, 2020. **20**(6): p. 355-362.
- 933 53. McGonagle, D., et al., *The Role of Cytokines including Interleukin-6 in COVID-19*
934 *induced Pneumonia and Macrophage Activation Syndrome-Like Disease*. Autoimmun
935 Rev, 2020. **19**(6): p. 102537.
- 936 54. Messner, C.B., et al., *Ultra-High-Throughput Clinical Proteomics Reveals Classifiers of*
937 *COVID-19 Infection*. Cell Syst, 2020. **11**(1): p. 11-24 e4.
- 938 55. Magro, C., et al., *Complement associated microvascular injury and thrombosis in the*
939 *pathogenesis of severe COVID-19 infection: A report of five cases*. Transl Res, 2020.
940 **220**: p. 1-13.
- 941 56. Macor, P., et al., *Multiple-Organ Complement Deposition on Vascular Endothelium in*
942 *COVID-19 Patients*. Biomedicines, 2021. **9**(8).
- 943 57. Yu, J., et al., *Direct activation of the alternative complement pathway by SARS-CoV-2*
944 *spike proteins is blocked by factor D inhibition*. Blood, 2020. **136**(18): p. 2080-2089.
- 945 58. Yang, Y.H., et al., *Autoantibodies against human epithelial cells and endothelial cells*
946 *after severe acute respiratory syndrome (SARS)-associated coronavirus infection*. J
947 Med Virol, 2005. **77**(1): p. 1-7.
- 948 59. Doran, A.C., A. Yurdagul, Jr., and I. Tabas, *Efferocytosis in health and disease*. Nat Rev
949 Immunol, 2020. **20**(4): p. 254-267.
- 950 60. Matthay, M.A., et al., *Acute respiratory distress syndrome*. Nat Rev Dis Primers, 2019.
951 **5**(1): p. 18.
- 952 61. Margaroli, C., et al., *Spatial mapping of SARS-CoV-2 and H1N1 lung injury identifies*
953 *differential transcriptional signatures*. Cell Rep Med, 2021. **2**(4): p. 100242.
- 954 62. Fernandez, I.E. and O. Eickelberg, *The impact of TGF-beta on lung fibrosis: from*
955 *targeting to biomarkers*. Proc Am Thorac Soc, 2012. **9**(3): p. 111-6.

- 956 63. Paavola, K.J., et al., *The Fibronectin-ILT3 Interaction Functions as a Stromal*
957 *Checkpoint that Suppresses Myeloid Cells*. *Cancer Immunol Res*, 2021. **9**(11): p. 1283-
958 1297.
- 959 64. Tomic, S., et al., *Reduced Expression of Autophagy Markers and Expansion of*
960 *Myeloid-Derived Suppressor Cells Correlate With Poor T Cell Response in Severe*
961 *COVID-19 Patients*. *Front Immunol*, 2021. **12**: p. 614599.
- 962 65. Fouet, G., et al., *Molecular Basis of Complement C1q Collagen-Like Region Interaction*
963 *with the Immunoglobulin-Like Receptor LAIR-1*. *Int J Mol Sci*, 2021. **22**(10).
- 964 66. Hadjadj, J., et al., *Impaired type I interferon activity and inflammatory responses in*
965 *severe COVID-19 patients*. *Science*, 2020. **369**(6504): p. 718-724.
- 966 67. Cizmecioglu, A., et al., *Apoptosis-induced T-cell lymphopenia is related to COVID-19*
967 *severity*. *J Med Virol*, 2021. **93**(5): p. 2867-2874.
- 968 68. Feng, Z., et al., *The Novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-*
969 *CoV-2) Directly Decimates Human Spleens and Lymph Nodes*. *medRxiv*, 2020: p.
970 2020.03.27.20045427.
- 971 69. Sethi, S., et al., *A proposal for standardized grading of chronic changes in native*
972 *kidney biopsy specimens*. *Kidney Int*, 2017. **91**(4): p. 787-789.
- 973 70. Ishak, K., et al., *Histological grading and staging of chronic hepatitis*. *J Hepatol*, 1995.
974 **22**(6): p. 696-9.
- 975 71. Gorkiewicz, G., et al., *Species-specific identification of campylobacters by partial 16S*
976 *rRNA gene sequencing*. *J Clin Microbiol*, 2003. **41**(6): p. 2537-46.
- 977 72. Corman, V.M., et al., *Detection of 2019 novel coronavirus (2019-nCoV) by real-time*
978 *RT-PCR*. *Euro Surveill*, 2020. **25**(3).
- 979 73. Hadfield, J., et al., *Nextstrain: real-time tracking of pathogen evolution*.
980 *Bioinformatics*, 2018. **34**(23): p. 4121-4123.
- 981 74. Sagulenko, P., V. Puller, and R.A. Neher, *TreeTime: Maximum-likelihood*
982 *phylogenetic analysis*. *Virus Evol*, 2018. **4**(1): p. vex042.
- 983 75. Dobin, A., et al., *STAR: ultrafast universal RNA-seq aligner*. *Bioinformatics*, 2013.
984 **29**(1): p. 15-21.
- 985 76. Langmead, B. and S.L. Salzberg, *Fast gapped-read alignment with Bowtie 2*. *Nat*
986 *Methods*, 2012. **9**(4): p. 357-9.
- 987 77. Robinson, M.D., D.J. McCarthy, and G.K. Smyth, *edgeR: a Bioconductor package for*
988 *differential expression analysis of digital gene expression data*. *Bioinformatics*, 2010.
989 **26**(1): p. 139-40.
- 990 78. Subramanian, A., et al., *Gene set enrichment analysis: a knowledge-based approach*
991 *for interpreting genome-wide expression profiles*. *Proc Natl Acad Sci U S A*, 2005.
992 **102**(43): p. 15545-50.
- 993 79. Qi, C., et al., *SCovid: single-cell atlases for exposing molecular characteristics of*
994 *COVID-19 across 10 human tissues*. *Nucleic Acids Res*, 2022. **50**(D1): p. D867-D874.
- 995 80. Segata, N., et al., *Metagenomic microbial community profiling using unique clade-*
996 *specific marker genes*. *Nat Methods*, 2012. **9**(8): p. 811-4.
- 997 81. Kostic, A.D., et al., *PathSeq: software to identify or discover microbes by deep*
998 *sequencing of human tissue*. *Nat Biotechnol*, 2011. **29**(5): p. 393-6.
- 999 82. Bolyen, E., et al., *Reproducible, interactive, scalable and extensible microbiome data*
1000 *science using QIIME 2*. *Nat Biotechnol*, 2019. **37**(8): p. 852-857.
- 1001 83. Callahan, B.J., et al., *DADA2: High-resolution sample inference from Illumina amplicon*
1002 *data*. *Nat Methods*, 2016. **13**(7): p. 581-3.

1003 84. Segata, N., et al., *Metagenomic biomarker discovery and explanation*. *Genome Biol*,
 1004 2011. **12**(6): p. R60.
 1005

1006


1007 **Supplemental Figures**



1008


1009 **Figure S1. Clinical courses of covid-19 cases.** X-axis specifies interval from SARS-CoV-2 positive
 1010 PCR. Treatment in the general ward and/or intensive care unit is shown. Start of ventilation
 1011 therapies is indicated by arrows. Covid-19 specific therapies are indicated.
 1012

1013




1014
1015
1016
1017
1018
1019
1020

Figure S2. Relation of SARS-CoV-2 cultivability and transcript levels determined by RNAseq (Mann-Whitney test).




1021
1022
1023
1024
1025
1026

Figure S3. Gross pathology representation of lung. (Top) Section through a lobe with DAD. The lung parenchyma is inhomogeneously colored and consolidated. **(Bottom)** A case with bacterial superinfection shows pus in bronchial lumina and on the cut surface of the lung.




1027
1028
1029
1030
1031
1032
1033
1034
1035
1036
1037

Figure S4. Histological representation of DAD in covid-19. (A) Exudative DAD with hyaline membranes (arrows) and lymphocytic interstitial infiltrates in alveolar septa (arrowhead). (B, C) Organizing DAD with intra-alveolar fibro-cellular infiltrates. (D) Multinucleated syncytial pneumocytes in organizing DAD (arrow). (E) Squamous metaplasia in organizing DAD (arrows). (F) Hemosiderin in alveolar septa and alveolar macrophages (arrows). (G-I) Pneumocyte nuclear atypia with macro-nucleoli (arrows; "owl-eye" in H). Atypical pneumocytes are often scaled off the alveolar membrane. In G also alveolar hemorrhage is evident. Inset in I shows ground-glass nuclear changes in atypical pneumocytes.




1038
1039
1040
1041
1042
1043

Figure S5. Immunohistochemical analyses of DAD. (A) Macrophage specific CD68 staining. Note the non-stained atypical pneumocytes (arrows). (B) Pneumocytes are scaled-off from the alveolar membrane (pneumocyte specific nuclear TTF-1 staining, arrows). (C, D) SARS-CoV-2 nucleoprotein staining of infected pneumocytes; asterisk (*) marks a hyaline membrane.




1044
1045
1046
1047
1048

Figure S6. Neutrophils and clinical parameters. Correlation analyses of neutrophil abundance (determined by deconvolution of RNAseq data with xCell) and clinical parameters (Spearman correlation, Mann-Whitney test).




1049
1050
1051
1052
1053
1054
1055
1056
1057
1058
1059
1060
1061
1062
1063
1064

Figure S7 Kidney histopathology. (A) PAS-stained kidney specimen with advanced diffuse and nodular diabetic glomerulosclerosis, advanced parenchymal atrophy and severe arteriolohyalinosis (100-fold). (B) PAS-stained kidney specimen showing segmental obliteration of glomerular capillary loops by fibrin thrombi (arrowheads), endothelitis of a glomerular arteriole (arrows) and accumulation of plasma in Bowman's space (asterisks; 200-fold). (C) Overview of an H&E-stained kidney specimen with diffuse lymphocytic tubulointerstitial nephritis (arrows; 20-fold). (D) H&E-stained kidney specimen showing severe tubular epithelial changes: loss of brush border, nuclear swelling and cytoplasmic vacuolisation. Note the tubulointerstitial inflammatory cell infiltrate, mainly consisting of lymphocytes with foci of tubulitis, as characterized by the presence of mononuclear cells on the basolateral aspect of the tubular epithelial cells (400-fold). (E, F) Immunohistochemical detection of SARS-CoV-2 nucleoprotein showing granular staining predominantly in the cytoplasm and occasionally in the nuclei of tubular epithelial cells of large distal tubules (100-fold & 600-fold, respectively).




1065
1066
1067
1068
1069
1070

Figure S8. Heart histopathology. (A) Fresh small scar in the myocardium. (B) Sparse subepicardial lymphocytic infiltrate. (C, D) Single plasma cells and lymphocytes in the endomysium around vessels.



1071
1072
1073
1074
1075
1076
1077
1078

Figure S9. Liver Histopathology. Morphological changes resembling sclerosing cholangitis COVID 19. (A) Preserved lobular architecture. Mild macrovesicular steatosis of the lobular parenchyma. Liver septum with mild lymphocytic infiltrates and septal bile duct adjacent to the A. hepatica branch surrounded by thick layer of condensed collagen fibers (50-fold; hematoxylin & eosin). (B) Sclerosis is highlighted by the sirius red connective tissue stain (50-fold; sirius red). (C) Portal tract with interlobular bile duct and periductal sclerosis.



1079

1080

1081


1082

1083


1084

1085


Figure S10. Dominant taxa identified by molecular methods and cultivation in covid-19 lungs. Shown is the relative abundance of 16S rRNA gene and ITS sequencing and microbial RNAseq data annotated with Metaphlan or Pathseq pipelines.




1086
1087 **Figure S11. Single cell transcriptomic analysis.** *C1q A, B* and *C* chains are mainly expressed
1088 by macrophages. Data derived from Xu et al [31] and analyzed with SCovid single-cell atlas
1089 database [79].
1090
1091



1092
1093
1094 **Figure S12. Single cell transcriptomic analysis.** *LAIR-1* is mainly expressed by macrophages.
1095 Data derived from Delorey et al [17] and analyzed with SCovid single-cell atlas database [79].
1096
1097




1098
1099
1100 **Figure S13. Transcriptomic correlation of *C1q*, *LAIR-1* and *LILRB4* from RNAseq.** Correlation
1101 of *C1q* chains with *LAIR-1* (top) and *LILRB4* (bottom; Spearman correlation).
1102



1103
1104
1105
1106
1107
1108

Figure S14. TGF beta 1 (12.5 kDa) western blots in covid-19 lung tissues and controls (reference human GAPDH).



1109
1110
1111
1112
1113

Figure S15. Inhibitory immune checkpoints in covid-19 and controls from RNAseq. Immune checkpoint inhibitor expression in covid-19 compared to controls (Mann-Whitney test).



1114
 1115 **Figure S16. Inhibitory immune checkpoints and cell types from RNAseq data.** Correlation
 1116 analysis of immune-checkpoints and cell types derived from xCell analysis (Spearman
 1117 correlation; p* < 0.05, p*** < 0.001).